Coya Therapeutics (COYA) News Today $5.72 +0.35 (+6.52%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Coya Therapeutics: How Fair Value analysis predicted 40% downside in biotech stockJune 12 at 2:40 AM | uk.investing.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from HC WainwrightJune 11 at 1:45 AM | americanbankingnews.comCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday.June 9, 2025 | marketbeat.comCoya Therapeutics secures patent for IL-2 liquid formulationJune 4, 2025 | uk.investing.comEquities Analysts Offer Predictions for COYA Q3 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for Coya Therapeutics in a research report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share ofMay 23, 2025 | marketbeat.comQ1 Earnings Estimate for COYA Issued By HC WainwrightCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Coya Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.50) forMay 22, 2025 | marketbeat.comChardan Capital Has Negative Outlook of COYA FY2025 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Investment analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Wednesday, May 14th. Chardan Capital analyst K. Nakae now expects that the company will postMay 21, 2025 | marketbeat.comCoya Therapeutics First Quarter 2025 Earnings: Misses ExpectationsMay 20, 2025 | finance.yahoo.comCoya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy RatingMay 19, 2025 | tipranks.comCoya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceMay 16, 2025 | businesswire.comDME Capital Management LP Buys 372,414 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA)DME Capital Management LP grew its stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 29.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,646,440 shares of the company's stockMay 10, 2025 | marketbeat.comCoya Therapeutics to Participate in Two Upcoming Conferences in May 2025May 8, 2025 | finance.yahoo.comSibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of DirectorsMay 8, 2025 | globenewswire.comCoya Therapeutics (COYA) to Release Earnings on ThursdayCoya Therapeutics (NASDAQ:COYA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-coya-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan CapitalChardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Monday.April 30, 2025 | marketbeat.comCoya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with ...April 26, 2025 | businesswire.comCoya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data ReleaseApril 25, 2025 | seekingalpha.comCoya Therapeutics reports interim results from IL-2, CTLA4-Ig combination studyApril 25, 2025 | markets.businessinsider.comPromising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline PotentialApril 25, 2025 | tipranks.comCoya Therapeutics' (COYA) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday.April 24, 2025 | marketbeat.comCoya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection ...April 23, 2025 | seekingalpha.comCoya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher - What's Next?Coya Therapeutics (NASDAQ:COYA) Trading Up 8.6% - What's Next?April 23, 2025 | marketbeat.comAtea Pharmaceuticals appoints Howard Berman to board of directorsApril 17, 2025 | markets.businessinsider.comIs Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 11, 2025 | insidermonkey.comIs Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 11, 2025 | msn.comAIGH Capital Management LLC Grows Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)AIGH Capital Management LLC lifted its position in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 85.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,201,152 shares of the company's stock after buying an additionalMarch 31, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Thursday.March 28, 2025 | marketbeat.comChardan Capital Has Strong Forecast for COYA FY2025 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the company will post eaMarch 28, 2025 | marketbeat.comCoya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome ProgramMarch 26, 2025 | businesswire.comCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday.March 21, 2025 | marketbeat.comCoya Therapeutics Reports 2024 Financial Results and ProgressMarch 21, 2025 | tipranks.comCoya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth PlansMarch 20, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPSCoya Therapeutics (NASDAQ:COYA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14.March 19, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday.March 19, 2025 | marketbeat.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comCoya Therapeutics Reports 2024 Financial Results and UpdatesMarch 18, 2025 | tipranks.comCoya Therapeutics (COYA) to Release Earnings on TuesdayCoya Therapeutics (NASDAQ:COYA) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)D. Boral Capital reiterated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Monday.March 10, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Trading Up 4.5% - Should You Buy?Coya Therapeutics (NASDAQ:COYA) Stock Price Up 4.5% - Should You Buy?March 4, 2025 | marketbeat.comCoya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and CombinationsFebruary 26, 2025 | businesswire.comCoya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and CombinationsFebruary 25, 2025 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Biohaven Ltd. (BHVN) and Arvinas Holding Company (ARVN)February 12, 2025 | markets.businessinsider.com70,000 Shares in Coya Therapeutics, Inc. (NASDAQ:COYA) Bought by Newbridge Financial Services Group Inc.Newbridge Financial Services Group Inc. acquired a new stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 70,000 shares of the cFebruary 10, 2025 | marketbeat.comCoya Therapeutics Now Pivots Toward Phase 2 In ALS And FTDFebruary 7, 2025 | seekingalpha.comCoya: A Few Catalysts On The Way For COYA-302 Makes This A Must WatchFebruary 7, 2025 | seekingalpha.comCoya: Low-Dose IL-2 in AD patients resulted in reduced proinflammatory markersFebruary 7, 2025 | markets.businessinsider.comBTIG maintains Coya Therapeutics stock buy rating, $15 targetFebruary 6, 2025 | msn.comCoya reports promising Alzheimer's treatment study resultsFebruary 6, 2025 | msn.comCoya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly DosingFebruary 6, 2025 | benzinga.comD. Boral Capital Reaffirms "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)D. Boral Capital restated a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Thursday.February 6, 2025 | marketbeat.com Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address COYA Media Mentions By Week COYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.650.88▲Average Medical News Sentiment COYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼52▲COYA Articles Average Week Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fulcrum Therapeutics News Today iTeos Therapeutics News Today Revance Therapeutics News Today MBX Biosciences News Today Checkpoint Therapeutics News Today Rezolute News Today Vigil Neuroscience News Today Solid Biosciences News Today ADC Therapeutics News Today Aquestive Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
